Jianru Chen

Dr. Jianru Chen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2020 in Medicinal Research Reviews
Verified
Journal Article
Open access
PDF file
JCJianru Chen
Jianru Chen
SLShuli Li
Shuli Li
CLChunying Li
Chunying Li
Vitiligo is an autoimmune depigment disease results from extensive melanocytes destruction. The destruction of melanocyte is thought to be of multifactorial causation. Genome‐wide associated studies have identified single‐nucleotide polymorphisms in a panel of susceptible loci as risk factors in melanocyte death. But vitiligo onset can't be solely attributed to a susceptive genetic background. Oxidative stress triggered by elevated levels of reactive oxygen species accounts for melanocytic molecular and organelle dysfunction, a minority of melanocyte demise, and melanocyte‐specific antigens exposure. Of note, the self‐responsive immune function directly contributes to the bulk of melanocyte deaths in vitiligo. The aberrantly heightened innate immunity, type‐1‐skewed T helper, and incompetent regulatory T cells tip the balance toward autoreaction and CD8+ cytotoxic T lymphocytes finally execute the killing of melanocytes, possibly alarmed by resident memory T cells. In addition to the well‐established apoptosis and necrosis, we discuss several death modalities like oxeiptosis, ferroptosis, and necroptosis that are probably employed in melanocyte destruction. This review focuses on the various mechanisms of melanocytic death in vitiligo pathogenesis to demonstrate a panorama of that. We hope to provide new insights into vitiligo pathogenesis and treatment strategies by the review.

29 September 2025 in Applied Intelligence
Verified
Journal Article
Closed access
PDF file
ZLZhiming Li
Zhiming Li
SJShuying Jiang
Shuying Jiang
FXFan Xiang
Fan Xiang
CLChunying Li
Chunying Li
SLShuli Li
Shuli Li
JZJunran Zhang
Junran Zhang

16 March 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QSQiong Shi
Qiong Shi
LLLin Liu
Lin Liu
JCJianru Chen
Jianru Chen
WZWeigang Zhang
Weigang Zhang
WGWeinan Guo
Weinan Guo
CLChunying Li
Chunying Li
Purpose: Acral melanoma is the major subtype of melanoma seen in Asian patients with melanoma and is featured by its insidious onset and poor prognosis. The genomic study that elucidates driving mutational events is fundamental to the development of gene-targeted therapy. However, research on genomic profiles of acral melanoma in Asian patients is still sparse. Experimental Design: We carried out whole-exome sequencing (WES) on 60 acral melanoma lesions (with 55 primary samples involved), targeted deep sequencing in a validation cohort of 48 cases, RNA sequencing in 37 acral melanoma samples (all from the 60 undergoing WES), and FISH in 233 acral melanoma specimens (54 of the 60 undergoing WES included). All the specimens were derived from Asian populations. Results: BRAF, NRAS, and KIT were discerned as significantly mutated genes (SMG) in acral melanoma. The detected COSMIC signature 3 related to DNA damage repair, along with the high genomic instability score, implied corresponding pathogenesis of acral melanoma. Moreover, the copy number gains of EP300 were associated with the response of acral melanoma to targeted therapy of A485 (a p300 inhibitor) and immune checkpoint blockade treatment. In addition, the temporal order in mutational processes of the samples was reconstructed, and copy-number alterations were identified as early mutational events. Conclusions: Our study provided a detailed view of genomic instability, potential therapeutic targets, and intratumoral heterogeneity of acral melanoma, which might fuel the development of personalized strategies for treating acral melanoma in Asian populations.

21 March 2023 in The Journal of Pathology
Verified
Journal Article
Closed access
JCJianru Chen
Jianru Chen
WGWeinan Guo
Weinan Guo
PDPengran Du
Pengran Du
TCTingting Cui
Tingting Cui
YYYuqi Yang
Yuqi Yang
CLChunying Li
Chunying Li

8 January 2024 in The Journal of Pathology
Verified
Journal Article
Closed access
PKPan Kang
Pan Kang
YWYinghan Wang
Yinghan Wang
JCJianru Chen
Jianru Chen
YCYuqian Chang
Yuqian Chang
WZWeigang Zhang
Weigang Zhang
CLChunying Li
Chunying Li

18 March 2025 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
HYHang Yin
Hang Yin
JCJianru Chen
Jianru Chen
CLChunying Li
Chunying Li